Home › Companies › Aldeyra Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Aldeyra Therapeutics, Inc.’s Form 8-K, filed 2026-06-10 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Aldeyra Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Aldeyra Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Todd C. Brady, M.D., Ph.D. | 23,026,101 | -- | -- | 1,081,762 | 20,038,067 | Majority: yes |
| Proposal 2: Ratification of Appointment of BDO USA, P.C | 43,693,772 | 321,501 | 130,657 | -- | -- | Majority: yes |
| Proposal 3: Advisory Vote on Executive Compensation | 19,477,504 | 4,543,221 | 87,138 | -- | 20,038,067 | Majority: yes |
Source: Aldeyra Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-10 — read the filing on EDGAR.
Each item below shows how the 124 asset managers that disclosed a Aldeyra Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Aldeyra Therapeutics, Inc.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation”): 19,477,504 for, 4,543,221 against, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,321,068 outstanding shares: 32% for, 8% against (40% of the company cast a for/against vote).
The 124 asset managers below cast 83% of the shares they voted on this item FOR (17,354,964 for, 3,506,172 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,609,558 | 2,165 | 0 | 0 | For |
| BlackRock | 2,474,501 | 666 | 0 | 0 | For |
| AQR | 1,975,176 | 0 | 0 | 0 | For |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 0 | 1,841,541 | 0 | 0 | Against |
| 683 Capital Management, LLC | 1,500,000 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,090,641 | 0 | 0 | 0 | For |
| DE Shaw | 1,040,003 | 0 | 0 | 0 | For |
| Fidelity | 929,180 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 777,895 | 0 | 0 | 0 | For |
| State Street | 703,444 | 552 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 671,330 | 0 | 0 | 0 | For |
| ARDSLEY ADVISORY PARTNERS LP | 0 | 350,000 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 0 | 340,878 | 0 | 0 | Against |
| Charles Schwab | 278,052 | 0 | 0 | 0 | For |
| WOODSTOCK CORP | 0 | 266,756 | 0 | 0 | Against |
| Two Sigma | 240,734 | 0 | 0 | 0 | For |
| Northern Trust | 214,135 | 0 | 0 | 0 | For |
| Dimensional | 0 | 212,385 | 0 | 0 | Against |
| T. Rowe Price | 189,396 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 186,186 | 0 | 0 | 0 | For |
| WELLS FARGO ADVISORS FINANCIAL NETWORK, LLC | 156,311 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 144,259 | 0 | 0 | Against |
| Equitable | 131,665 | 0 | 0 | 0 | For |
| Goldman Sachs | 123,699 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 94,968 | 0 | 0 | Against |
Showing the 25 largest of 124 asset managers. See all 124 in the interactive database.
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Aldeyra Therapeutics, Inc.’s own tally for this item (“Elect Director: Todd C. Brady, M.D., Ph.D.”): 23,026,101 for, 1,081,762 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,321,068 outstanding shares: 38% for, 2% withheld (40% of the company cast a for/withheld vote).
The 40 asset managers below cast 100% of the shares they voted on this item FOR (5,982,074 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,251,013 | 0 | 4,402 | 0 | For |
| BlackRock | 940,905 | 0 | 0 | 0 | For |
| Fidelity | 915,583 | 0 | 0 | 0 | For |
| Charles Schwab | 139,026 | 0 | 0 | 0 | For |
| Equitable | 131,665 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 120,844 | 0 | Abstain |
| Goldman Sachs | 104,164 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 82,124 | 0 | 0 | 0 | For |
| Lincoln Financial | 36,000 | 0 | 10,494 | 0 | For |
| T. Rowe Price | 41,852 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 40,205 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 37,120 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 26,818 | 0 | 0 | 0 | For |
| Global X | 26,067 | 0 | 0 | 0 | For |
| Russell Investments | 25,961 | 0 | 0 | 0 | For |
| Pacific Life | 21,814 | 0 | 0 | 0 | For |
| TIAA | 21,266 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 21,117 | 0 | Abstain |
| CLEARWATER INVESTMENT TRUST | 16,989 | 0 | 0 | 0 | For |
| Northern Trust | 16,597 | 0 | 0 | 0 | For |
| John Hancock | 16,322 | 0 | 0 | 0 | For |
| Nationwide | 15,849 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 14,342 | 0 | 0 | 0 | For |
| Prudential/PGIM | 0 | 0 | 9,920 | 0 | Abstain |
| Voya | 9,448 | 0 | 0 | 0 | For |
Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.2% Majority: yes · of votes cast
Aldeyra Therapeutics, Inc.’s own tally for this item (“Proposal 2: Ratification of Appointment of BDO USA, P.C”): 43,693,772 for, 321,501 against, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,321,068 outstanding shares: 72% for, 0.6% against (73% of the company cast a for/against vote).
The 40 asset managers below cast 100% of the shares they voted on this item FOR (6,156,667 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,255,414 | 0 | 0 | 0 | For |
| BlackRock | 940,905 | 0 | 0 | 0 | For |
| Fidelity | 915,583 | 0 | 0 | 0 | For |
| Charles Schwab | 139,026 | 0 | 0 | 0 | For |
| Equitable | 131,665 | 0 | 0 | 0 | For |
| Dimensional | 120,844 | 0 | 0 | 0 | For |
| Goldman Sachs | 104,164 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 82,124 | 0 | 0 | 0 | For |
| Lincoln Financial | 46,494 | 0 | 0 | 0 | For |
| T. Rowe Price | 41,852 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 40,205 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 37,120 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 26,818 | 0 | 0 | 0 | For |
| Global X | 26,067 | 0 | 0 | 0 | For |
| Russell Investments | 25,961 | 0 | 0 | 0 | For |
| Pacific Life | 21,814 | 0 | 0 | 0 | For |
| TIAA | 21,266 | 0 | 0 | 0 | For |
| Jackson National | 21,117 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 16,989 | 0 | 0 | 0 | For |
| Northern Trust | 16,597 | 0 | 0 | 0 | For |
| John Hancock | 16,322 | 0 | 0 | 0 | For |
| Nationwide | 15,849 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 14,342 | 0 | 0 | 0 | For |
| Prudential/PGIM | 9,920 | 0 | 0 | 0 | For |
| Voya | 9,448 | 0 | 0 | 0 | For |
Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.
Ranked by the number of Aldeyra Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 60,321,068 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.99% |
| 2 | BlackRock | 4.10% |
| 3 | AQR | 3.27% |
| 4 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 3.05% |
| 5 | 683 Capital Management, LLC | 2.49% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.81% |
| 7 | DE Shaw | 1.72% |
| 8 | Fidelity | 1.54% |
| 9 | ACADIAN ASSET MANAGEMENT LLC | 1.29% |
| 10 | State Street | 1.17% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 6.24% | 13F |
| Vanguard Group | 6.13% | 13F |
| D.E. Shaw | 2.33% | 13F |
| State Street | 1.86% | 13F |
| Millennium Management | 1.65% | 13F |
| Renaissance Technologies | 1.43% | 13F |
| Morgan Stanley | 1.09% | 13F |
| Dimensional Fund Advisors | 1.03% | 13F |
Percentages above are of 60,321,068 shares outstanding, as reported by Aldeyra Therapeutics, Inc. on its Form 10-Q dated 2026-05-05 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Aldeyra Therapeutics, Inc.’s 10-Q dated 2026-05-05. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Aldeyra Therapeutics, Inc.'s shareholder meeting held 2026-06-09, in the 2025-2026 proxy season, 124 asset managers reported how they voted on 3 ballot items in their SEC Form N-PX filings, covering 469 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of Aldeyra Therapeutics, Inc.'s… — FOR was 81% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Aldeyra Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-10.
Aldeyra Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).